(Total Views: 616)
Posted On: 05/05/2020 9:32:50 AM
Post# of 148934
Re: Crujones1985 #32166
Please read transcript of Wallstreet Reporter:
ANSWER—DR. POURHASSAN
“Manufacturing, manufacturing, and manufacturing. [28:48] We have a solution to the world, we potentially have. We’re waiting in desperate, desperate days. These are very valuable days we are waiting and I have gotten hold of Dr. xxxxx at Samsung. That’s the only company that can produce whatever we need. AGC is not capable of producing that kind of volume, but they’re doing a good job giving us the small volumes. But we could get 1.2 million doses this year and I have heard that Gilead is prepared for 130,000 patients, and to get any more from them will have to wait until next year.” “So, we’re ahead of them. We’re way ahead of them, because we could have 1.2 million if not more, but we need to get funding to get Samsung to expedite everything. And I’m not able to use shareholder value because the company doesn’t belong to me, it belongs to the shareholders, and we don’t want to dilute the company because that’s not what our shareholders want. So, we need the government to help us…… work with the data.”
It is crystallclear he expects more demand than Samsung can supply, so having AGC with small amounts of manufacturing Leronlimab, he is starting to get another big one with worldwide production capacity in Belgium, United States, Japan, and India....
That says a lot, but it will take a while till filling service production is approved!
ANSWER—DR. POURHASSAN
“Manufacturing, manufacturing, and manufacturing. [28:48] We have a solution to the world, we potentially have. We’re waiting in desperate, desperate days. These are very valuable days we are waiting and I have gotten hold of Dr. xxxxx at Samsung. That’s the only company that can produce whatever we need. AGC is not capable of producing that kind of volume, but they’re doing a good job giving us the small volumes. But we could get 1.2 million doses this year and I have heard that Gilead is prepared for 130,000 patients, and to get any more from them will have to wait until next year.” “So, we’re ahead of them. We’re way ahead of them, because we could have 1.2 million if not more, but we need to get funding to get Samsung to expedite everything. And I’m not able to use shareholder value because the company doesn’t belong to me, it belongs to the shareholders, and we don’t want to dilute the company because that’s not what our shareholders want. So, we need the government to help us…… work with the data.”
It is crystallclear he expects more demand than Samsung can supply, so having AGC with small amounts of manufacturing Leronlimab, he is starting to get another big one with worldwide production capacity in Belgium, United States, Japan, and India....
That says a lot, but it will take a while till filling service production is approved!
(1)
(0)Scroll down for more posts ▼
